Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study

Steven A Lubitz, Anthony Z Faranesh, Caitlin Selvaggi, Steven J Atlas, David D McManus, Daniel E Singer, Sherry Pagoto, Michael V McConnell, Alexandros Pantelopoulos, Andrea S Foulkes, Steven A Lubitz, Anthony Z Faranesh, Caitlin Selvaggi, Steven J Atlas, David D McManus, Daniel E Singer, Sherry Pagoto, Michael V McConnell, Alexandros Pantelopoulos, Andrea S Foulkes

Abstract

Background: Morbidity from undiagnosed atrial fibrillation (AF) may be preventable with early detection. Many consumer wearables contain optical photoplethysmography (PPG) sensors to measure pulse rate. PPG-based software algorithms that detect irregular heart rhythms may identify undiagnosed AF in large populations using wearables, but minimizing false-positive detections is essential.

Methods: We performed a prospective remote clinical trial to examine a novel PPG-based algorithm for detecting undiagnosed AF from a range of wrist-worn devices. Adults aged ≥22 years in the United States without AF, using compatible wearable Fitbit devices and Android or iOS smartphones, were included. PPG data were analyzed using a novel algorithm that examines overlapping 5-minute pulse windows (tachograms). Eligible participants with an irregular heart rhythm detection (IHRD), defined as 11 consecutive irregular tachograms, were invited to schedule a telehealth visit and were mailed a 1-week ambulatory ECG patch monitor. The primary outcome was the positive predictive value of the first IHRD during ECG patch monitoring for concurrent AF.

Results: A total of 455 699 participants enrolled (median age 47 years, 71% female, 73% White) between May 6 and October 1, 2020. IHRDs occurred for 4728 (1%) participants, and 2070 (4%) participants aged ≥65 years during a median of 122 (interquartile range, 110-134) days at risk for an IHRD. Among 1057 participants with an IHRD notification and subsequent analyzable ECG patch monitor, AF was present in 340 (32.2%). Of the 225 participants with another IHRD during ECG patch monitoring, 221 had concurrent AF on the ECG and 4 did not, resulting in an IHRD positive predictive value of 98.2% (95% CI, 95.5%-99.5%). For participants aged ≥65 years, the IHRD positive predictive value was 97.0% (95% CI, 91.4%-99.4%).

Conclusions: A novel PPG software algorithm for wearable Fitbit devices exhibited a high positive predictive value for concurrent AF and identified participants likely to have AF on subsequent ECG patch monitoring. Wearable devices may facilitate identifying individuals with undiagnosed AF.

Registration: URL: https://www.

Clinicaltrials: gov; Unique identifier: NCT04380415.

Keywords: atrial fibrillation; diagnostic screening programs; digital technology; photoplethysmography; wearable electronic devices.

Figures

Figure 1.
Figure 1.
Participant flow through the trial. IHRD indicates irregular heart rhythm detection.
Figure 2.
Figure 2.
Irregular heart rhythm detection frequency and confirmed atrial fibrillation or flutter. Plots demonstrating the fraction of participants receiving an irregular heart rhythm detection (IHRD) notification (A), fraction of participants with an IHRD notification with confirmed atrial fibrillation (AF) or flutter on a subsequent ECG patch monitor (B), and IHRD positive predictive value (PPV) for AF, as confirmed on a concurrent ECG patch monitor (C).
Figure 3.
Figure 3.
Burden and duration of atrial fibrillation or flutter among 340 participants with confirmed arrhythmia during ECG patch monitoring. Plots demonstrating the burden of atrial fibrillation (AF) or flutter among participants with confirmed arrhythmia on the ECG patch monitor (A) and the duration of the longest AF episode during ECG patch monitoring (B).

References

    1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, et al. . Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143:e254–e743. doi: 10.1161/CIR.0000000000000950
    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867. doi: 10.7326/0003-4819-146-12-200706190-00007
    1. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, et al. . Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050–2060. doi: 10.1001/jama.2013.280521
    1. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D, et al. . Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020;382:20–28. doi: 10.1056/NEJMoa1817591
    1. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, et al. . Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909–1917. doi: 10.1056/NEJMoa1901183
    1. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, et al. . Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol. 2019;74:2365–2375. doi: 10.1016/j.jacc.2019.08.019
    1. De Novo Classification Request for Irregular Rhythm Notification Feature. Food and Drug Administration. Accessed August 8, 2018. .
    1. Irregular rhythm notification instructions for use (IFU). Apple Inc. Accessed March 24, 2022.
    1. Lubitz SA, Faranesh AZ, Atlas SJ, McManus DD, Singer DE, Pagoto S, Pantelopoulos A, Foulkes AS. Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: the Fitbit heart study. Am Heart J. 2021;238:16–26. doi: 10.1016/j.ahj.2021.04.003
    1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–272. doi: 10.1378/chest.09-1584
    1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457.
    1. Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, Carter C, Baca-Motes K, Felicione E, Sarich T, et al. . Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA. 2018;320:146–155. doi: 10.1001/jama.2018.8102
    1. Gladstone DJ, Wachter R, Schmalstieg-Bahr K, Quinn FR, Hummers E, Ivers N, Marsden T, Thornton A, Djuric A, Suerbaum J, et al. . Screening for atrial fibrillation in the older population: a randomized clinical trial. JAMA Cardiol. 2021;6:558–567. doi: 10.1001/jamacardio.2021.0038
    1. Rooney MR, Soliman EZ, Lutsey PL, Norby FL, Loehr LR, Mosley TH, Zhang M, Gottesman RF, Coresh J, Folsom AR, et al. . Prevalence and characteristics of subclinical atrial fibrillation in a community-dwelling elderly population: the ARIC study. Circ Arrhythm Electrophysiol. 2019;12:e007390. doi: 10.1161/CIRCEP.119.007390
    1. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J, Than CT, Keung EK, Singer DE. Atrial fibrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. Circ Arrhythm Electrophysiol. 2015;8:1040–1047. doi: 10.1161/CIRCEP.114.003057
    1. Van Gelder IC, Healey JS, Crijns HJGM, Wang J, Hohnloser SH, Gold MR, Capucci A, Lau C-P, Morillo CA, Hobbelt AH, et al. . Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38:1339–1344. doi: 10.1093/eurheartj/ehx042
    1. Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, Harrison TN, Liu TI, Solomon MD. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study. JAMA Cardiol. 2018;3:601–608. doi: 10.1001/jamacardio.2018.1176
    1. Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score. Circulation. 2019;140:1639–1646. doi: 10.1161/CIRCULATIONAHA.119.041303
    1. Pratap A, Neto EC, Snyder P, Stepnowsky C, Elhadad N, Grant D, Mohebbi MH, Mooney S, Suver C, Wilbanks J, et al. . Indicators of retention in remote digital health studies: a cross-study evaluation of 100,000 participants. NPJ Digit Med. 2020;3:21. doi: 10.1038/s41746-020-0224-8
    1. Editors; Rubin E. Striving for diversity in research studies. N Engl J Med. 2021;385:1429–1430. doi: 10.1056/NEJMe2114651
    1. A study to investigate if early atrial fibrillation (AF) diagnosis reduces risk of events like stroke in the real-world. Accessed November 25, 2021. .

Source: PubMed

3
Se inscrever